EUVIMEDEUVIMED entdecken
Crossref

Comparison of the effects of multiple intravitreal bevacizumab injections and single triamcinolone acetonide injection in diabetic macular edema

MohammedM Elwan, HossamY Abouelkheir

Journal of the Egyptian Ophthalmological Society · 2013

DOI: 10.4103/2090-0686.127355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Egyptian Ophthalmological Society, 2013. Verfasst von MohammedM Elwan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeThe aim of this study was to compare the effects of a single intravitreal injection of triamcinolone acetonide versus three consecutive monthly intravitreal injections of bevacizumab for the treatment of diabetic macular edema.Patients and methodsIn this prospective, randomized study, patients were divided into two groups: 15 eyes that were treated with three consecutive monthly intravitreal injections of 1.25 mg bevacizumab (bevacizumab group) and 15 eyes treated with single intravitreal injections of 4 mg triamcinolone acetonide (triamcinolone group). Changes in the best-corrected visual acuity (BCVA), intraocular pressure, and optical coherence tomography measurements were evaluated in both groups. Follow-up visits up to 3 months from baseline were reported.ResultsThe bevacizumab group showed a significant decrease in the median central foveal thickness from 236 μm ± 91.5 to 221 μm ± 43.5 after 3 months (P < 0.05). The triamcinolone group also showed a significant reduction in central foveal thickness from 339 μm ± 130.5 to 273 μm ± 84.5 (P < 0.05). The bevacizumab group showed an increase in the BCVA from a median of 0.8 ± 0.45 logMAR to a median of 0.48 ± 0.3 logMAR after 3 months (P < 0.05). The triamcinolone group also showed an increase in BCVA from a median of 0.7 ± 0.18 logMAR to a median of 0.3 ± 0.41 logMAR (P < 0.05). Statistical analysis showed no significant difference between both groups at 3 months.ConclusionA single intravitreal injection of triamcinolone acetonide is as effective as three consecutive monthly intravitreal injections of bevacizumab for the treatment of diabetic macular edema.

Zitieren

APA

Elwan, M., & Abouelkheir, H. (2013). Comparison of the effects of multiple intravitreal bevacizumab injections and single triamcinolone acetonide injection in diabetic macular edema. Journal of the Egyptian Ophthalmological Society. https://doi.org/10.4103/2090-0686.127355

Vancouver

Elwan M, Abouelkheir H. Comparison of the effects of multiple intravitreal bevacizumab injections and single triamcinolone acetonide injection in diabetic macular edema. Journal of the Egyptian Ophthalmological Society. 2013. doi:10.4103/2090-0686.127355

BibTeX
@article{Elwan2013,
  author = {Elwan, MohammedM and Abouelkheir, HossamY},
  title = {Comparison of the effects of multiple intravitreal bevacizumab injections and single triamcinolone acetonide injection in diabetic macular edema},
  journal = {Journal of the Egyptian Ophthalmological Society},
  year = {2013},
  doi = {10.4103/2090-0686.127355}
}
Kostenlos starten →